Evidence map›Paper›PMID 41268290›Full record

ArticleAmerican journal of translational research2025

Clinical efficacy and short-term prognosis of belimumab in the treatment of systemic lupus erythematosus in children.

Yu Fang, Zhi Chen, Wei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yu FangDepartment of Pediatric Rheumatology and Immunology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China Chengdu 611731, Sichuan, China.
Zhi ChenDepartment of Pediatric Rheumatology and Immunology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China Chengdu 611731, Sichuan, China.
Wei ZhangDepartment of Pediatric Rheumatology and Immunology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China Chengdu 611731, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the clinical efficacy and short-term prognosis of belimumab in treating pediatric systemic lupus erythematosus (SLE).

methodsA retrospective analysis was conducted on 208 pediatric patients with SLE who were admitted to our hospital between June 2019 and May 2023. Patients who received conventional glucocorticoid (GCs) treatment were assigned to the control group (n=118), while those who received GCs combined with belimumab were assigned to the observation group (n=90).

resultsThe observation group exhibited a higher total effective rate, faster symptom improvement, and a lower SLEDAI-2K score (all

conclusionsConventional glucocorticoid therapy combined with belimumab effectively enhances treatment outcomes in pediatric SLE patients, reduces the risk of short-term recurrence, and does not increase adverse reactions.

Indexed as

belimumabChildrenefficacy and prognosisglucocorticoidsimmunosuppressive agentssystemic lupus erythematosus

Identifiers

PMID41268290
PMCPMC12628220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.